SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue slipped marginally during the December 2021 quarter. A decline of about Rs. 37706.60 millions was observed as compared to Rs. 38696.80 millions during the corresponding quarter last year.Net profit stood at Rs. 5154.30  millions  compared to Rs. 4669.20 millions in the corresponding previous quarter,high by 10.39%.The company reported a good operating profit of 9616.20 millions compared to 8390.90 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 37706.60 38696.80 -2.56 112397.60 103636.90 8.45 128032.10 125319.30 2.16
Other Income 3132.50 501.90 524.13 7966.40 2110.80 277.41 1502.20 15109.20 -90.06
PBIDT 9616.20 8390.90 14.60 27994.50 21051.70 32.98 30862.20 42225.70 -26.91
Interest 854.70 743.20 15.00 2951.70 1593.50 85.23 2569.80 4080.10 -37.02
PBDT 8761.50 7647.70 14.56 25042.80 19458.20 28.70 27396.80 38145.60 -28.18
Depreciation 3552.40 3050.00 16.47 8398.00 7537.60 11.41 5868.10 5615.60 4.50
PBT 5209.10 4597.70 13.30 16644.80 11920.60 39.63 21528.70 32530.00 -33.82
TAX 54.80 -71.50 -176.64 -793.20 -305.10 159.98 131.70 418.60 -68.54
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 5154.30 4669.20 10.39 17438.00 12225.70 42.63 21397.00 32111.40 -33.37
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 25.50 21.68 17.61 24.91 20.31 22.62 24.11 33.69 -28.46

Sun Pharma Inds. Share Price

1670.40 -4.80 (-0.29%)
20-Apr-2026 12:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.40
Dr. Reddys Lab 1236.50
Cipla 1234.30
Zydus Lifesciences 942.40
Lupin 2332.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×